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Abstract
Improving early detection of colorectal cancer (CRC) is a key public health priority as adenomas and stage I cancer can
be treated with minimally invasive procedures. Population screening strategies based on detection of occult blood in
the feces have contributed to enhance detection rates of localized disease, but new approaches based on genetic
analyses able to increase specificity and sensitivity could provide additional advantages compared to current
screening methodologies. Recently, circulating cell-free DNA (cfDNA) has received much attention as a cancer
biomarker for its ability to monitor the progression of advanced disease, predict tumor recurrence and reflect the
complex genetic heterogeneity of cancers. Here, we tested whether analysis of cfDNA is a viable tool to enhance
detection of colon adenomas. To address this, we assessed a cohort of patients with adenomas and healthy controls
using droplet digital PCR (ddPCR) and mutation-specific assays targeted to trunk mutations. Additionally, we
performed multiregional, targeted next-generation sequencing (NGS) of adenomas and unmasked extensive
heterogeneity, affecting known drivers such as APC, KRAS and mismatch repair (MMR) genes. However, tumor-related
mutations were undetectable in patients’ plasma. Finally, we employed a preclinical mouse model of Apc-driven
intestinal adenomas and confirmed the inability to identify tumor-related alterations via cfDNA, despite the enhanced
disease burden displayed by this experimental cancer model. Therefore, we conclude that benign colon lesions display
extensive genetic heterogeneity, that they are not prone to release DNA into the circulation and are unlikely to be
reliably detected with liquid biopsies, at least with the current technologies.
Introduction
Colorectal cancer (CRC) is the third most common
malignancy, causing over 50,000 deaths per year in the
United States1. CRC develops from precursor adenoma
lesions through two major routes. Constitutive Wnt sig-
naling, triggered by inactivation of the tumor suppressor
gene APC, followed by mutations in codons 12 and 13 of
the KRAS oncogene, characterize the traditional CRC
pathway originating from tubular adenomas (TAs), villous
adenomas (VAs) and mixed tubulovillous adenomas
(TVAs)2. The serrated pathway, arising from sessile ser-
rated adenomas (SSAs), hyperplastic polyps (HPs) and
traditional serrated adenomas (TSAs), is instead char-
acterized by microsatellite instability, fostered by inacti-
vation of the MMR, methylation of CpG islands and
mutations in the BRAF oncogene, especially the most
common glutamate to valine substitution in position 6003.
CRC displays remarkable therapeutic resilience, fostered
by widespread genetic heterogeneity4–6. Cancer mutations
are categorized as truncal or clonal when they originate
from the initial tumor-founder clone and are ubiquitous
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throughout the neoplasia, whereas mutations present only
in a subset of tumor regions are known as subclonal or
private7. The heterogeneity of CRC is shaped by neutral
evolution, with mutations spreading in the absence of
Darwinian selection and clonal sweeps4,5, but its origin
remains controversial. The “Big Bang” model suggests
that the majority of somatic alterations arise during the
initial stages of tumorigenesis, ahead of the emergence of
detectable adenomas4. Accordingly, most private muta-
tions are pervasive throughout the neoplasia because their
accumulation occurs swiftly after the establishment of an
initial founder clone that harbors all truncal mutations.
However, the monoclonal origin of CRC has been brought
into question by genetic analysis of individual colonic
crypts of benign adenomas, in which polyclonality of
driver events, including distinct mutations in APC and
KRAS, has been identified8,9.
Survival of patients with CRC depends on tumor stage
at diagnosis. Removal of adenomas and stage I cancers
through polypectomy at colonoscopy and/or surgery is
largely curative10. In order to improve diagnosis of early
cancers, in England, the Bowel Cancer Screening Pro-
gramme (BCSP) offers guaiac Fecal Occult Blood test
(gFOBt) biennially to individuals aged 60 to 74 years. The
BCSP has improved the detection rate of early-stage
cancers and has reduced mortality11–13. However, the test
has limited sensitivity for right-sided tumors12,13 and for
benign adenomas14–16, and the rate of false-positive and
negative results is noteworthy13. The test also suffers
modest uptake of around 50%13,17. In an attempt to
improve detection rate and compliance, the BCSP will
replace gFOBt with the Fecal Immunochemical Test,
which has improved sensitivity and diagnostic accuracy,
all from a single stool sample, as opposed to the multiple
sampling required with gFOBt15,18,19.
One attractive possibility to improve detection of ade-
nomas and compliance is the implementation of diag-
nostic tests that exploit analysis of cell-free DNA
(cfDNA). Dying cells release fragmented DNA into the
circulation, and in cancer patients the fraction of cfDNA
that originates from tumor cells (circulating tumor DNA
(ctDNA)) carries tumor-related alterations, which can be
detected using next-generation sequencing (NGS) and
PCR-based methodologies20. Analysis of cfDNA, known
as liquid biopsy, is cost effective, minimally invasive, and
its specificity can be enhanced by tailoring the analysis
towards the detection of tumor-specific mutations21.
Recently, liquid biopsies have been used to detect minimal
residual disease and track recurrence after surgical
resection of localized disease. Patient-specific PCR assays
successfully amplified somatic aberrations in serial plasma
samples of post-operative CRC patients (stages I–IV),
enabling identification of relapses with an average lead
time of 10 months before clinical manifestation of the
disease22. Consistently, postsurgical detection of ctDNA
successfully predicted recurrence after surgical removal of
stage II CRC23. In contrast, the application of liquid
biopsies for detection of benign tumors has proved chal-
lenging24,25. The probability of detecting ctDNA is low in
early-stage CRC25 and different groups have reported
dissimilar results with regard to the diagnostic value of
total cfDNA levels or analysis of KRAS mutations in
plasma of patients with adenomas26–29. Encouraging
studies reported an increase in total cfDNA or even
detected tumor-related mutations in patients with benign
adenomas26,28. Notwithstanding their validity, these stu-
dies employed clinically impractical technologies, such as
radioactive-based dot-blot hybriditation28, or analyzed
patient cohorts comprising large adenomas26. Therefore,
the wider applicability of ctDNA analysis for detection of
low-grade, benign lesions is yet to be ascertained.
Several parameters might influence the detection rate of
benign lesions. Adenomas are typically small and do not
manifest the sustained apoptosis or necrosis observed in
advanced cancers. Moreover, tumor heterogeneity can
affect cfDNA analysis, as plasma representation of
trunk alterations is higher compared to subclonal muta-
tions30–32. Intriguingly, heterogeneity has been described
in adenomas, which also affects KRAS8,9, suggesting that
this oncogene might be subclonal and therefore inade-
quate for targeted cfDNA testing. Notwithstanding, the
advent of highly sensitive technologies, such as droplet
digital PCR (ddPCR), provides a cost-effective and effi-
cient way to identify low-frequency DNA mutations in
plasma, enabling more effective testing of the diagnostic
usefulness of plasma DNA analysis for early disease
detection.
Here, we assessed a cohort of individuals recruited
through the BCSP (Fig. 1) to test the feasibility of cfDNA
analysis for the detection of benign colorectal adenomas.
To that end, we searched for significant changes in total
cfDNA and for tumor-related mutations in the plasma of
patients with adenomas, using ddPCR and mutation-
specific assays tailored to trunk mutations identified by
multiregional targeted NGS of adenoma tissues. While
changes in cfDNA or mutations were not detectable, NGS
analysis unmasked extensive genetic heterogeneity of
colonic adenomas, affecting known drivers such as APC,
KRAS and MMR genes. Finally, using a mouse model of
Apc-driven intestinal adenomas, we confirmed that,
despite enhanced tumor burden, no alterations could be
identified in the cfDNA.
Results
Assessment of BRAF and KRAS mutations in adenomas
DNA from 76 formalin-fixed, paraffin-embedded
(FFPE) adenoma specimens, mostly low-grade and small
lesions (Fig. 1), was tested to identify mutations in KRAS
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and BRAF oncogenes. BRAF has been reported to be
mutated in 10% of CRC and to be the main driver of the
serrated pathway, whereas KRAS mutations are mutually
exclusive to BRAF and affect 40% of CRC33,34. With the
exception of the commercially available KRAS-c.38
mutation assay for ddPCR, BRAF and KRAS mutations
were detected employing degenerate assays developed in-
house (see Materials and methods). Hence, for each
sample, four assays were run to check for BRAF-c.1799,
KRAS-c.34 and KRAS-c.35 mutations by quantitative PCR
(qPCR), and the KRAS-c.38G>A substitution by ddPCR.
Wild-type (WT) allele PCR was run in parallel and sam-
ples were considered positive when mutations were
detected at a fractional abundance above 1%.
We identified 39 cases (51%) bearing mutations in
either KRAS or BRAF. The BRAF-c.1799 hotspot muta-
tions were identified in 4 out of 76 cases (5%), a frequency
lower than what has been reported33,34 (Supplemental
Fig. 1), but in agreement with other published data35. All
four BRAF-positive cases were from the recto-sigmoid
region, with 3 classified as HPs and 1 as a low-grade VA.
KRAS mutations were identified in 35 out of 76 cases
(46%) (Table 1). Among these KRAS-positive cases,
mutations at c.35G were the most common with 27 cases
(42%), including 11 TVA cases, 8 TAs, 4 VAs and 1
benign HP. Mutations at codon 34 were detected in 8
cases (10.5%), including 4 TVA cases, 2 TA adenomas and
1 VA lesion (Table 2). Finally, mutations at the base c.38G
were found in 9 cases (22.4%): 7 TVAs cases and 2 TAs
(Table 3). Interestingly, most patients showed varying
degrees of fractional abundance of the mutated alleles.
This variability could depend on contamination from the
stromal tissue, since tumor enrichment by microdissec-
tion was not performed in this experiment, but it could
also signify heterogeneity of the mutant oncogenes. The
latter possibility was confirmed by the identification of
double KRAS mutations in the same adenomas in over
10% of patients (9/76). Indeed, 5 adenomas showed
simultaneous mutations in codons 35 and 38, in 3 speci-
mens both the 34 and 35 hotspots were mutated, and in
1 patient specimen codons 34 and 38 were both affected.
Double mutations affecting KRAS codons 12 and 13 were
already observed in colon neoplasia8,36. The simultaneous
presence of multiple mutations in KRAS suggests tumor
heterogeneity in early adenomas.
Quantification of total cfDNA levels
The cases that were positive for at least one BRAF or
KRAS mutation were selected for quantitative analysis of
the total amount of cfDNA to test the hypothesis that
elevated cfDNA levels are associated with the presence of
early neoplastic lesions26. The control group consisted of
37 individuals who had a negative colonoscopy outcome
following referral for a false-positive gFOBt result. The
mean total cfDNA concentration was slightly higher in
the control group (7.5 ± 0.64 ng/mL) compared to the
patient group (6.3 ± 0.6 ng/mL), but this difference was
7%
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Fig. 1 Clinicopathological information of patient samples. All data
were obtained from histology reports for the 76 patient cases.
a Distribution of different histological subtypes of adenomas. A small
portion of lesions (6%) showed focal adenocarcinoma (AC) within
adenomatous regions. b Pathology assessment showed that most
were low-grade lesions (82%). c Half of the lesions were found in the
sigmoid colon (49%), with a significant portion located in the rectum
(16%). The rest were distributed throughout the colon. d Longest
measurements of diameter listed on histology report were used;
measurements of FFPE sections were used as proxy when a report did
not state any measurements
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not statistically significant (p= 0.19; Fig. 2). The cfDNA
yield in the control group did not show any overt devia-
tion from control cohorts described in other studies26,37.
On the other hand, the cfDNA levels in the adenoma
group were lower than previously reported26. The inclu-
sion of patients with early, small-sized adenomas in our
analysis might explain, at least partially, the inability to
identify any increase in cfDNA. Notwithstanding, our data
indicate that no discernible alteration in total plasma
cfDNA concentrations exists in patients with pre-
cancerous lesions compared to healthy subjects. A lack of
significant increase in total plasma cfDNA levels in indi-
viduals with premalignant colon lesions has also been
reported by others29.
Analysis of KRAS and BRAF mutations in plasma
The lack of an increase in plasma cfDNA levels does not
necessarily exclude the possibility that tumor-specific
mutations might be detected in the cfDNA. Therefore, we
sought to investigate whether BRAF and KRAS mutations
identified in the FFPE specimens were represented in the
matched plasma samples. First, we assessed the sensitivity
of mutation assays using ddPCR and found that mutant
DNA was detectable below a 0.5% allele frequency (Sup-
plemental Fig. 2). Then, using ddPCR, we tested matched
plasma samples from 4 BRAF mutant cases, 8 KRAS-
c.34G-positive cases, 27 KRAS-c.35G-positive cases and
9 patient cases bearing the KRAS-c.38 (Fig. 3). Variable
copy numbers of WT KRAS and BRAF genes were
Table 1 Histology details of KRAS-c.35G mutant adenomas
Sample ID No. of FFPE blocks % Fractional abundance in FFPE samples Histology Polyp dimensions (mm)
H146 1 9.4001 Transverse (benign HP) 8 × 5 × 4
H151 1 3.1402 Splenic flexure (LG TA) 5 × 4
H154 4 0.0000–10.8343 Descending-sigmoid (LG TA/TVA) 17 × 15 × 14
H185 1 1.2587 Sigmoid (LG TVA) 10 × 8 × 17
H189 1 18.612 Rectal (LG TA) 12
H263 11 0.0000–6.2256 Rectal (LG+HG TVA, focal AC) 17 × 30 × 10−30 × 25 × 22
H265 13 19.5678–37.4255 Distal sigmoid (LG+HG VA) 55 × 35 × 20
H266 9 12.9668–26.7434 Sigmoid (LG VA) N/A
H321 1 0.9613 Colonic (LG+HG TVA) 15 × 7
H325 1 1.0923 Colonic (LG TVA) 20 × 14 × 8
H329 2 4.5123–9.0246 Rectal (LG VA) 11 × 9 × 9−14 × 9 × 7
H333 2 6.2192–8.3315 Recto-sigmoid (LG TA) 19 × 16 × 10
H334 2 0.0000–1.5870 Recto-sigmoid (LG TA+TVA) 7 × 9 × 4–12 × 10 × 4
H335 2 2.8364–8.9973 Sigmoid-cecal (LG TVA) 10–12
H336 2 5.3522–11.8328 Sigmoid (LG TVA) 14
H339 2 0.0005–1.2086 Recto-sigmoid (LG TA) 6 × 5 × 5−12 × 8 × 8
H343 2 0.7317–1.3000 Sigmoid (LG TVA) 15 × 10 × 15
H344 2 2.1852–2.8104 Colonic (LG TVA) 20 × 20 × 10
H345 2 0.0016–1.5049 Descending-sigmoid (LG TA) 7 × 5 × 4–11 × 9 × 7
H346 2 0.0003–2.5250 Ascending-rectal (LG TA) 12−15
H347 2 0.7243–1.8001 Recto-sigmoid (LG TVA) 21 × 15 × 10
H693 2 0.3259–1.6247 Cecal (LG TA) N/A
H696 2 7.0348–7.4390 Ascending (LG TVA) N/A
H697 1 5.4522 Cecal (LG TA) 10 × 4 × 2
H774 2 9.3524–18.4350 Cecal (AC Duke’s B) N/A
H783 2 13.9502–14.6877 Distal descending (HG TVA with focal AC) N/A
H784 2 18.9137–23.7891 Colonic (polyp–HG VA, AC–invasive, pT1) N/A
For cases where more than one FFPE blocks were tested, lowest and highest mutation frequencies are reported
HP hyperplastic polyp, LG low-grade, HG high-grade, TA tubular adenoma, VA villous adenoma, TVA tubulovillous adenoma, MD mild
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detected and numerous patients had robust representa-
tion of the WT DNA. However, we were unable to
identify with confidence mutant DNA copies in the cir-
culating DNA in all the cases analyzed. Indeed, the
sporadic positive samples showed a limited number of
droplets and fractional mutations below the minimum
value predicted by the Poisson distribution analysis (not
shown). For example, with regard to KRAS-c.35, 4 samples
showed marginal positivity for the mutant alleles (Fig. 3a),
over a range of fractional abundances (from 0.029% in
sample H335 to 0.294% in H693). Poisson analysis pre-
dicted detection of 0.0–0.6 mutant copies at the minimum
threshold (not shown), pointing towards random posi-
tivity. Indeed, when positive samples were retested, all but
one failed to confirm the initially identified mutations.
Overall, these results indicate that ctDNA in adenoma
patients is not reliably detectable by ddPCR.
Multi-regional targeted sequencing of adenomas
Data from FFPE tissue suggested that the BRAF and
KRAS mutations were present at low mutational fraction
in most cases. We cannot formally rule out that such poor
representation of mutant DNA depends on stromal
dilution of the tumor cells. However, it is likewise rea-
sonable that genetic heterogeneity defines colon adeno-
mas and that KRAS and BRAF mutations are subclonal.
Moreover, the private nature of these oncogenic altera-
tions might have contributed to their absence from the
patients’ plasma. To assess the degree of heterogeneity in
early colon lesions, six adenoma specimens (H149, H154,
Table 2 Histology details of KRAS-c.34G mutant adenomas
Sample ID No. of FFPE
blocks
% Fractional abundance in
FFPE samples
Histology Polyp dimensions (mm)
H183 1 0.9667 Mid transverse (LG TA) 10 × 6
H314 1 2.7618 Distal sigmoid (LG TA) 16 × 7 × 5
H325 1 1.0923 Colonic (LG TVA) 20 × 14 × 8
H329 2 0.0006–5.3010 Rectal (LG VA) 11 × 9 × 9
14 × 9 × 7
H338 2 0.7336–3.5509 Sigmoid (LG TVA) 16 × 15 × 10
H344 2 0.0000–1.9799 Colonic (LG TVA) 20 × 20 × 10
H775 1 11.093 Colonic (MD AC, Duke’s C1) N/A
H785 1 9.0330 Recto-sigmoid (sessile HG TVA,
focal pT1 AC)
16 × 11 × 9
Histology and polyp dimensions were obtained from the histology reports. For cases where more than one FFPE blocks were tested, lowest and highest mutation
frequencies are reported
LG low-grade, HG high-grade, TA tubular adenoma, VA villous adenoma, TVA tubulovillous adenoma, MD mild differentiated, AC adenocarcinoma
Table 3 Histology details of KRAS-c.38G mutant adenomas
Sample ID No. of FFPE blocks % Fractional abundance in FFPE samples Histology Polyp dimensions (mm)
H142 1 16.3347 Sigmoid (LG TVA) 17 × 10 × 15
H149 8 0.0000–3.8205 Sigmoid (LG TVA) 15 × 15 × 15–25 × 20 × 25
H151 1 5.0351 Splenic flexure (LG TA) 5 × 4
H183 1 6.2698 Mid transverse(LG TA) 10 × 6
H190 1 30.4348 Recto-sigmoid (LG TVA) 14
H334 2 0.0000–4.6363 Recto-sigmoid (LG TA+TVA) 7 × 9 × 4–12 × 10 × 4
H335 2 0.0565–1.4967 Sigmoid-cecal (LG TVA) 10–12
H336 2 2.3732–7.1057 Sigmoid (LG TVA) 14
H347 2 0.0500–2.1894 Recto-sigmoid (LG TVA) 21 × 15 × 10
For cases where more than one FFPE blocks were tested, lowest and highest mutation frequencies are reported
LG low-grade, HG high-grade, TA tubular adenoma, VA villous adenoma, TVA tubulovillous adenoma, MD mild differentiated, AC adenocarcinoma
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H263, H264, H265 and H266) (Supplemental Table 1)
were selected for multiregional targeted NGS. Sequencing
was carried out using an in-house custom targeted panel,
which includes the most common alterations in CRC,
including hotspot mutations in 116 genes, 22 genes
recurrently amplified/deleted, 51 copy number regions,
121 microsatellite regions and 2 RSpondin gene fusions.
Prior to sequencing, the adenomas were analyzed by a
pathologist to identify the tumor area for macroscopic
enrichment (Supplemental Table 1). DNA aliquots were
quantified using the described ALU real-time PCR assay
and approximately 200 ng of purified DNA per sample
was sequenced on the Illumina NGS platform. The
average sequencing depth obtained was 696× (minimum
461×, maximum 1059×).
As shown in Fig. 4, all the sequenced samples revealed
widespread tumor heterogeneity, affecting various driver
genes among which, remarkably, were alterations in MMR
genes. Often non-ubiquitous mutations were identified in
several spatially distinct tumor regions, a behavior com-
patible with the pervasive nature of private mutations
described in the “Big Bang” model of tumorigenesis4.
With regard to KRAS, in some cases oncogenic muta-
tions were ubiquitous (see for example c.35G>C/p.G12A
for patient H265, or the c.35G>A/p.G12D mutation in
case H266; Fig. 4e, f), suggesting that these might be
truncal variants. However, in other adenomas KRAS
substitutions displayed remarkable heterogeneity. In case
Fig. 2 Comparison of total plasma cfDNA levels in the patient
and control groups. Comparing total plasma cfDNA levels in the
patient (n= 39) and the control (n= 37) groups. Each dot represents
one sample. Horizontal bars represent mean ± SD. The mean total
cfDNA levels were 7.456 ± 0.642 ng/mL for the control group and
6.285 ± 0.599 ng/mL for the patient group (p= 0.186, two-tailed t-test)
Fig. 3 Assessment of KRAS mutations in plasma samples. Bar charts show merged data from two runs for each patient sample. The number of
WT (green bars) and mutant (blue bars) copies detected are shown on left y-axis. The total number of droplets analyzed (gray dots) are indicated on
right y-axis. a KRAS-c.35; b KRAS-c.34; c KRAS-c.38. The “+ve con” indicates positive control from 10 ng of genomic DNA isolated from SW480 (c.35G>T/
p.G12V) CRC cell line, A549 (c.34G>A/p.G12S) lung cancer cell line, and HCT116 (c.38G>A/p.G13D) CRC cell line. The “–ve con” indicates negative
control from 10 ng of hgDNA. NTC no template control
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Gene Protein H263-3 H263-4 H263-6 H263-8
H263-
10/1
APC p.R876* 7 15 29 7 0
APC p.Q1429* 41 47 36 43 55
BCLAF1 p.S262fs*76 21 19 21 21 22
CARD11 p.? 28 30 31 24 26
CDC27 p.? 2 0 0 0 0
ELF3 p.K356* 21 18 0 25 32
EP400 p.A449S 45 46 47 51 49
EZH2 p.? 89 80 89 87 89
FGFR1 p.? 0 6 0 0 0
FGFR1 p.? 0 10 0 0 0
FGFR2 p.? 0 13 0 0 0
KRAS p.G12D 0 13 31 5 0
KRAS p.G13D 16 17 0 19 34
MAP3K4 p.P36_E37ins 23 15 13 19 23
MLH1 p.K751R 50 55 46 47 46
MLL2 p.R3727H 0 0 0 0 14
MSH2 p.I704V 55 53 49 47 49
PIK3CA p.H1047R 0 10 29 9 0
% mutant
reads
0
50
100
Gene Protein H154-3 H154-4
APC p.R876* 40 28
APC p.L1489fs*23 22 24
APC p.L1489F 7 4
CDKN2A P.? 0 18
CREBBP p.N1978S 53 52
FGFR1 p.? 6 7
FLT1 p.E201A 50 48
KLF5 p.? 34 35
KRAS p.G12V 28 20
KRAS p.G13D 0 6
MLH1 p.D74H 10 12
MSH3 p.A57_A65del 9 11
MSH3 p.P64A 19 0
PTCH1 p.E967G 48 46
SETD2 p.M1889T 47 50
SOX9 p.S279fs*1 25 20
TBX3 p.E332fs*6 22 21
TCF7L2 p.K462* 31 20
% mutant
reads
0
50
100
Gene Protein H149-5 H149-6 H149-7 H149-8 H149-11 H149-12
APC p.? 25 33 26 39 19 23
APC p.R213* 26 31 29 30 18 24
ATM p.I2275T 54 49 49 52 51 45
ERBB2 p.R288Q 53 48 52 54 48 49
ERBB3 p.G668E 0 15 0 0 0 0
EZH2 p.? 44 49 40 40 44 46
FGFR1 p.? 0 8 0 0 0 0
FGFR1 p.? 0 8 9 0 0 0
FGFR2 p.? 24 0 0 0 0 0
FGFR2 p.? 0 0 0 0 0 13
MSH3 p.A57_A65del 13 10 6 8 9 9
MSH3 p.P63A 0 0 11 11 17 0
MSH3 p.P64A 0 0 15 13 0 0
SETD2 p.R493W 20 25 29 34 0 0
SMAD4 p.? 33 0 0 0 0 0
TRRAP p.T2114S 52 50 51 51 46 50
% mutant
reads
0
50
100
B)
A)
C)
Fig. 4 (See legend on next page.)
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% mutant
reads
0
50
100
Gene Protein H266-1 H266-2 H266-3 H266-5
H266-
7/1
H266-
7/2
APC p.Q1338* 44 50 47 41 48 43
APC p.R213* 38 43 39 39 44 37
BAI3 p.I98K 0 4 0 0 0 0
CBL p.? 24 28 50 37 29 47
CDC27 p.I91fs*54 5 0 0 0 0 0
CSPP1 p.S459L 0 0 0 14 9 17
EZH2 p.? 0 0 0 88 86 87
FBXW7 p.R465H 0 0 11 39 8 16
FLT1 p.? 47 52 46 44 47 49
GNAS p.R844H 35 44 48 42 43 39
IRS2 p.A701ins 16 17 16 14 16 16
IRS2 p.H1328R 50 47 47 43 47 47
KLF5 p.? 29 30 27 24 32 31
KRAS p.G12D 42 45 46 39 41 37
MLL2 p.R5179H 19 24 0 0 0 0
MSH3 p.A57_A65del 8 7 7 8 11 6
MSH3 p.P63A 0 6 0 6 0 7
MSH3 p.P64A 0 8 7 9 0 11
PTCH1 p.G325S 55 62 47 41 50 47
SOX9 p.S223fs*1 12 15 17 24 18 16
TP53 p.R273C 58 63 52 40 56 46
TPTE p.S128C 0 0 8 25 5 13
Gene Protein H265-2 H265-3
H265-
4/1
H265-
5/1
H265-
5/2
H265-
6/1
H265-
7/1
APC p.P1221fs*45 33 31 28 31 36 33 30
APC p.E1397* 46 38 39 43 45 46 44
APC p.? 0 7 0 0 0 0 0
BCL9L p.S410P 0 9 0 0 0 0
BCL9L p.T1179P 0 10 0 0 0 0 0
CDC27 p.? 0 2 0 0 0 0 0
CDK8 p.Q122H 49 46 47 48 48 46 51
ERBB4 p.R525C 0 0 0 6 14 0 0
EZH2 p.? 86 83 86 84 89 83 89
FAM123B p.K238N 19 0 0 0 0 0 0
FGFR1 p.? 0 9 0 0 0 0 0
FGFR1 p.? 0 8 11 0 0 7 10
FGFR2 p.? 13 0 0 0 0 0 12
FGFR2 p.? 0 12 0 12 0 16 0
GNAS p.R844H 37 35 32 35 39 46 42
JAK2 p.? 52 47 45 57 45 50 51
JAK2 p.? 0 0 0 33 0 0 0
KLF5 p.? 29 0 26 0 0 0 0
KLF5 p.? 0 26 0 26 31 21 26
KRAS p.G12A 41 42 32 39 39 36 40
MAP3K4 p.? 42 52 54 44 48 46 45
MSH3 p.A57_A65del 10 8 7 14 9 9 9
PCBP1 p.L100Q 41 44 37 45 45 43 43
TPTE p.D530E 4 0 0 9 8 0 0
% mutant
reads
0
50
100
Gene Protein H264-1 H264-2 H264-5 H264-8
APC p.N1161fs*3 14 20 10 11
ATM p.Y1442H 50 49 50 47
ATR p.H2437Y 8 0 0 0
CDC27 p.Y537H 0 5 0 0
DUSP16 p.? 51 46 43 39
ERBB4 p.A30T 5 0 0 0
EZH2 p.? 88 88 91 88
MSH3 p.A57_A65del 10 8 5 9
MSH3 p.P63A 0 5 9 9
MSH3 p.P64A 0 8 12 13
MSH3 p.? 0 0 7 0
PIK3CA p.? 0 7 0 0
SMAD4 p.? 56 53 52 46
TP53 p.? 19 25 17 11
% mutant
reads
0
50
100
E)
D)
F)
Fig. 4 Summary of multiregional sequencing data. Venn diagrams illustrate the spatial distributions of mutations in the different sequenced
regions of the indicated patients. Each colored oval represents one sequenced region. Mutations in red are driver mutations as determined by the in-
house calling algorithm. The heat maps show the percentage of mutant reads for each mutation. a Data for case H149, b data for case H154, c data
for case H263, d data for case H264, e data for case H265 and f data for case H266
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H263, the neoplasia harbored two KRAS mutations: 3 out
of 5 sequenced regions were positive for the c.35G>A/
G12D mutation at 5–31% frequencies, and 4 out of 5
regions were positive for the c.38G>A/p.G13D mutation
at 16–34% frequencies (Fig. 4c). Similarly, heterogeneity
was identified in case H154 (Fig. 4b), where two spatially
separated adenoma regions were sequenced and again two
distinct KRAS mutations were detected (c.34G>T/p.G12V
and c.38G>A/p.G13D). The c.38G>T substitution was
detected only in one tumor region and at a very low fre-
quency (6%), indicating that the mutation is present in a
relatively small clone. We were able to confirm the KRAS
mutational status using PCR analysis of the different
regions selected for NGS (Supplemental Table 2-4).
Next, we used ddPCR to confirm 5 additional patient-
specific mutations in FFPE samples. We also assessed
DNA isolated from matched white blood cells, to exclude
the possibility of germline variants, and we analyzed
plasma cfDNA to test whether ddPCR assays might
detect early adenomas. We selected the APC c.4285C>T
(p.Q1429*) mutation and the PIK3CA c.3140A>G
(p.H1047R) mutation in patient H263. The APC mutation
at codon 1429, a non-sense substitution, resulting in a
STOP codon, was identified at high frequencies in all five
sequenced samples, suggesting that this was a truncal
variant. We selected another APC mutation, c.4189G>T
(p.E1397*) from case H265, which also appeared truncal.
The remaining two targets were chosen from case H266:
APC (c.4012C>T/p.Q1338*) and TP53 (c.817C>T/p.
R273C). Both targets were ubiquitous and displayed high
mutational frequencies (41–50% for APC-Q1338* and
40–63% for TP53-R273C). ddPCR probe-based assays
were designed and validated for each mutation (Supple-
mental Figs. 3-7), and then tested to confirm the NGS
data in FFPE-derived DNA and, potentially, in plasma
cfDNA. All the five mutations were confirmed to be
tumor-specific alterations and were not detected in white
blood cells. However, despite selecting for ubiquitous
alterations, we were unable to detect any mutation in the
plasma-derived DNA (Fig. 5).
cfDNA dynamics in a mouse model of colon adenomas
Our inability to detect cfDNA alterations from benign
adenomas might reflect modest cfDNA release and/or
insufficient tumor burden. To investigate whether
enhanced tumor burden could enable detection of
cfDNA, we employed the Lgr5-EGFP-IRES-CreERT2+/0;
Apcfl/fl (Lgr5CreER-Apcfl/fl) mouse model of colon tumor-
igenesis38. In these animals, tamoxifen-inducible CreER
recombinase enables the deletion of the loxP-floxed exon
14 of Apc (Apcfl/fl) in the Lgr5-positive crypt intestinal
stem cells, triggering activation of the Wnt pathway and
development of multiple adenomas38–40. A total of
17 mice (10 females, 7 males) aged 9–12 months were
tested. The Apc-deleted group consisted of 8 tamoxifen-
injected Lgr5CreER-Apcfl/fl mice. The control group con-
sisted of 6 tamoxifen-injected Apcfl/fl mice (with no
expression of the Cre recombinase) and 3 vehicle-injected
Lgr5CreER-Apcfl/fl animals. As expected, Apc-deleted mice
developed multiple neoplastic lesions (between 4 to 36
macroadenomas, Supplemental Figure 8). To analyze the
levels of total cfDNA in these animals, we used an in-
house-developed assay targeting the mouse Gadph pseu-
dogenes41,42. Plasma samples from the Apc-deleted tren-
ded towards increased levels of total cfDNA (66.74 ng/
mL), compared to the controls (31.22 ng/mL), but without
reaching statistical significance (Fig. 6). To determine
whether tumor-specific alterations could be detected in
the plasma of the Apc-deleted mice, we designed and
validated ddPCR assays for identification of the recom-
bined and non-recombined Apcfl/fl alleles (Supplemental
Figure 9 and Supplemental Methods). The assays were
specific for the different alleles (Supplemental Figure 10A)
and enabled detection of the recombined Apc gene in the
intestinal tissue of tamoxifen-injected Lgr5CreER-Apcfl/fl
mice (Supplemental Figure 10B). However, we were
unable to detect recombined Apc in the matched cfDNA
(Supplemental Figure 10C). To further validate our Apc
allele assays, in a second experiment we collected fecal
material on a weekly basis, before plasma collection at
endpoint. Our ddPCR assays succeeded in detecting
increased fractional abundance of recombined Apc allele
in the stool DNA (Supplemental Figure 10D), but not in
plasma cfDNA (not shown).
Overall, these data indicate that, despite enhanced
tumor burden, ctDNA analysis is unable to identify
benign colon lesions.
Discussion
The implementation of liquid biopsies for detection of
early cancer remains challenging21. Many studies have
provided evidence of cfDNA utility in detecting localized
cancers or identifying minimal residual disease and pre-
dicting risk of recurrence in postsurgical CRC patients
with stage I–IV disease22,23,43. However, efforts to detect
benign lesions using liquid biopsies have yielded con-
trasting results26,29. Here, we have used orthologous
approaches to investigate the usefulness of cfDNA testing
in patients with benign polyps recruited to the BCSP. We
initially measured the levels of total cfDNA, under the
auspices that higher levels of cfDNA could discriminate
adenoma patients from healthy controls. However, we did
not detect significant differences between the two groups.
These data contrast with reports by others which suggest
that changes in cfDNA reflect the presence of adeno-
mas26. The reasons behind this discrepancy are unclear;
variations in sample storage, processing and methodolo-
gies might be responsible for the different results. We also
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Fig. 5 (See legend on next page.)
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employed a ddPCR platform to seek KRAS and BRAF
mutations in the plasma of patients bearing mutated
adenomas. Again, despite the high sensitivity of our
ddPCR assay (<1%), we were unable to confidently iden-
tify circulating mutant DNA in our patient cohort.
However, we cannot exclude that more elaborate tech-
nologies, such as BEAMing (beads, emulsion, amplifica-
tion, and magnetics), CAPP-Seq (cancer personalized
profiling by deep sequencing) or CUT-PCR (CRISPR-
mediated, Ultrasensitive detection of Target DNA-
PCR)44–48, could be successful with such challenging
plasma samples.
Notably, when assessing KRAS mutational status in
tumors, we frequently detected low mutational fractions
and observed the coexistence of multiple KRAS mutations
in the same patient sample. Multiregional sequencing
confirmed widespread genetic heterogeneity in six ade-
noma samples, which affected known driver genes and
confirmed the heterogeneous nature of KRAS mutations.
This finding is of relevance, considering that similar
results have been reported in the analysis of single crypts
isolated from benign human adenomas, where multiple
KRAS mutations have been detected, leading to the
hypothesis of a polyclonal origin of CRC8. However,
genetic analysis of established CRC indicates that KRAS
mutations are truncal in nature and putatively acquired
within an initial founder clone4,5. This apparent
conundrum awaits explanation. Perhaps sampling of
carcinomas has so far been too limited to identify het-
erogeneous KRAS mutations in relatively small clones, or,
alternatively, during the progression from adenomas to
carcinoma a clonal sweeping event might establish a
founder KRAS mutant clone. Of note, under therapeutic
selective pressure, the emergence of distinct KRAS
mutations has been reported in the plasma of CRC
patients with ensuing resistance to anti-EGFR therapy49.
Regardless, the widespread heterogeneity of colorectal
lesions is a serious deterrent to any therapeutic approach
and emphasizes the necessity of developing effective
strategies for the early detection and primary prevention
of intestinal cancers50,51.
We also exploited NGS data to design patient-specific
assays targeting trunk mutations for analysis of cfDNA, to
leverage on experimental evidence showing higher
abundance of trunk mutations in plasma30–32. However,
we were unable to validate any mutations in the plasma-
derived DNA. This consistent inability to identify tumor-
related changes in cfDNA exposes the reluctance of
benign lesions to shed DNA into the circulation. Of note,
in postsurgical patients, plasma tumor mutations can be
detected and monitored in the absence of clinical mani-
festations of the disease22,23,31,52–55, suggesting that
advanced malignancies shed DNA even in the presence of
low tumor burden. To better assess the relationship
between benign tumors and cfDNA, we employed the
Lgr5CreER-Apcfl/fl mouse model of intestinal neoplasia,
which develops multiple adenomas following constitutive
activation of the Wnt pathway in the intestinal stem
cells38, enabling us to evaluate the impact of increased
tumor burden on the dynamics of cfDNA. Similarly, we
failed to observe significant changes in total cfDNA in
mouse plasma, confirming our results in human samples.
Moreover, we designed ddPCR assays to detect the spe-
cific recombined Apc locus produced through Cre-
mediated recombination, to serve as a surrogate bio-
marker of cancer-related mutations. With this approach
we demonstrated that recombined DNA can be detected
in DNA isolated from intestinal tissue and stool, but again
our efforts to detect mutant DNA copies in plasma proved
unsuccessful.
In summary, we report widespread genetic hetero-
geneity within colon adenomas and show that this
(see figure on previous page)
Fig. 5 Analysis of patient-specific mutations using ddPCR. For each assay, one-dimensional (1D) amplitude plots are shown on the left with the
associated manual threshold gating (pink line) for VIC (WT, green) and FAM (mutant, blue) amplitudes. On the right, the bar graphs plot the number of
WT copies (green bars) and mutant copies (blue bars) detected on the left y-axis. Number of total droplets analyzed (gray dots) are shown on the right
y-axis. a Case H266 APC-c.4012C>T (p.Q1338*) mutation; b Case H265, APC-c.4189G>T (p.E1397*) mutation; c Case H263, APC-c.4285C>T (p.Q1429*)
mutation; d Case H266, TP53-c.817C>T (p.R273C) mutation; e Case H263, PI3K-c.3140A>G (p.H1047R) mutation. For each sample, 10 ng hgDNA was
used as a negative control, 10 ng of matched FFPE tissue DNA was used as a positive control and 10 ng of matched white blood cell (WBC) DNA was
included as a control for germline polymorphic variants. NTC no template control
Fig. 6 Total cfDNA quantities in the plasma of control and Apc-
deleted mice. The plasma cfDNA load was quantified using in-house-
developed mouse Gapdh assay. Each sample was run in duplicates.
The box and whisker plots compare total cfDNA loads between two
study groups. P= 0.092, Mann–Whitney test (n= 8 control and n= 7
Apc-deleted mice)
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heterogeneity affects genes and pathways functionally
associated with the development of CRC, such as APC,
KRAS and the MMR. Moreover, after thorough testing of
human and mouse plasma samples, we argue that benign
lesions do not release significant quantities of DNA in the
circulation and are therefore unlikely to be amenable to
diagnosis with liquid biopsies, at least using current
technologies.
Materials and methods
Patients
Colonoscopy, surgical resection and blood sample col-
lection were carried out at the Glenfield Hospital, Leice-
ster, UK, as part of the national BCSP. All patients
consented for their biological samples to be used in the
study “Biomarkers for Bowel Disease (2011)” (UHL study
11005; NREC 10/H0408/116). The study received ethical
approval from the Bowel Cancer Screening Programme
Research Committee and Ethics Approval UHL 11005.
Venous blood samples (15–20mL) were collected 1–4 h
prior to colonoscopy or surgical resection, processed
within 2 h of collection and stored at −80 °C. Out of 131
patient cases, 76 patient cases (58 males, 18 females; age
57–87 years, average 67.5 years) presented with pre-
cancerous lesions (Fig. 1). For cases with multiple FFPE
blocks, all available samples were included for analysis.
The control group consisted of 37 individuals (22 males,
15 females; age 60–74 years, average 64.8 years) who
participated in the program but showed no clinically
observable polyps following false-positive gFOBt results.
Additional diagnosis was noted for 8 individuals in the
control group: 4 had diverticulosis, 3 had ulcerative colitis
and 1 had angioectasia.
DNA extraction from FFPE tissue and human plasma
For the FFPE samples, DNA was extracted from a
minimum of three 4 μm FFPE sections per sample using
GeneReadTM DNA FFPE tissue kit (Qiagen®). Sections
were de-waxed in xylene and re-hydrated by serial
immersions in Industrial Methylated Spirit (IMS) before
DNA extraction was carried out as per the manufacturer’s
instructions. For the plasma samples, DNA was extracted
from 2.5–3mL plasma per patient using QIAamp® Cir-
culating Nucleic Acid kit (Qiagen®). Samples were stored
at −80 °C and thawed to room temperature prior to the
extraction. The manufacturer’s protocol for the extraction
using a QIAvac 24 Plus vacuum manifold (Qiagen®) was
followed for this process. All plasma eluates were stored
in 1.5 mL DNA LoBind micro-centrifuge tubes (Eppen-
dorf®). Additionally, all plasma cfDNA samples were
lyophilized prior to mutation detection analyses. Lyophi-
lization was performed using the VirTis BenchTop
Pro Freeze Dryer with OmnitronicsTM (SP Scientific).
Samples (40–70 μL) were flash-frozen in liquid nitrogen,
lyophilized for approximately 3 h and reconstituted in
5–25 μL H2O for 2 h at 4 °C before testing.
Animal study
All in vivo studies with Lgr5CreER-Apcfl/fl mice were
carried out under the project licence (PPL) no. 60/4370
granted by the Home Office. Animal studies were con-
ducted at the Preclinical Research Facility, University of
Leicester, UK. Mice were housed in a climate-controlled
environment with a 12 h day/night cycle and fed EURo-
dent Diet 14% (5LF2*). Intraperitoneal injection of
tamoxifen (10 mg/mL tamoxifen in sunflower oil) was
used to induce loss of Apc in mice. The vehicle control
was prepared by mixing sunflower seed oil and absolute
ethanol in a 9:1 ratio at room temperature. Mice were
injected with 100 μL/10 g of body weight. All the study
mice were monitored by trained staff at the Preclinical
Research Facility, University of Leicester, UK. Mice with
Lgr5CreER-Apcfl/fl were allocated randomly to tamoxifen
injection or vehicle control. Sample size was not deter-
mined by power analysis.
Small intestine and colon were harvested and fixed in
10% formalin overnight before being processed for par-
affin embedment by Core Biotechnological Services,
University of Leicester, UK. Small intestine was divided
into 3 or 6 sections and Swiss-rolled for embedding. Small
pieces of tissue (approximately 3 × 3mm) were also col-
lected from each tissue section and stored at −80 °C for
DNA extraction. Haematoxylin and eosin (H&E) staining
of FFPE samples was performed to examine any patho-
logical changes in the tissues. H&E staining was per-
formed by Core Biotechnological Services at University of
Leicester, UK. Histological images were acquired with
NanoZoomer-XR digital slide scanner.
DNA extraction from murine tissue, stool and blood
plasma
Intestinal tissue DNA was extracted using the DNeasy®
Blood & Tissue Kit (Qiagen®). Frozen tissues stored at
either −20 °C or −80 °C were left to equilibrate to room
temperature, and were cut into small pieces (maximum
weight= 25 mg). Then, 180 μL buffer ATL and 20 μL
Proteinase K were added and samples were digested at
56 °C overnight. Next, samples were left to cool and 4 μL
100mg/mL RNase A was added. Following this, 400 μL
each of buffer AL and 100% ethanol were added. Samples
were loaded onto the DNeasy membrane columns. Col-
umns were washed with 500 μL Buffer AW1 by cen-
trifugation at 6000 × g for 1 min and 500 μL of Buffer
AW2 by centrifugation at 20,000 × g for 3 min. DNA was
eluted with 70 μL Buffer AE by centrifugation at 6000 × g
for 1 min.
Blood was collected in 1.3 mL EDTA-coated tubes (K3E,
TEKLAB™) by cardiac puncture under terminal anesthesia
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with isofluorane. Tubes were kept on ice and plasma was
isolated within 2 h by sequential centrifugation at 1000 × g
for 10 min and then at 2000 × g for 15 min to remove
residual cellular components. Plasma volumes ranged
from 150 to 900 μL and samples were stored at −80 °C
until use. QIAmp® DNA Blood Mini Kit (Qiagen®) was
used for DNA isolation. For plasma samples below
200 μL, phosphate-buffered saline was added to reach 200
μL minimum volume. Proteins were digested by adding
Qiagen protease (10 μL per 100 μL plasma). Buffer AL was
added in a 1:1 ratio and incubated at 56 °C for 20min.
After incubation, 100% ethanol was added in a 1:1 ratio
and the resulting solution was passed through the QIAmp
silica-gel membrane columns by centrifugation at
6000 × g for 1 min. Column washing and eluting steps
were as described above.
Feces were collected on a weekly basis. For collection,
each mouse was transferred to a sterile cage, monitored
until excretion of fecal material and the collected sample
immediately snap-frozen in liquid nitrogen and stored
at −80 °C. Quantities of fecal samples collected ranged
from 9 to 234mg (median= 39mg). DNA was extracted
using the QIAamp® Fast DNA Stool Mini Kit (Qiagen®)
according to the manufacturer’s instruction. Eluted DNA
samples were stored at −20 °C.
Multiregional targeted NGS of patient adenoma samples
NGS analysis for FFPE samples (n=30) from 6 patient
cases (H149, H154, H263, H264, H265 and H266) was
performed at the Wellcome Sanger Institute, Cam-
bridge, UK, using a customized targeted CRC panel
(SureSelect, Agilent, UK) consisting of all coding exons
of 116 genes, 22 genes recurrently amplified/deleted,
51 copy number regions, 121 MSI regions and 2 gene
fusions (RSPO2 and 3). Samples were fragmented to an
average insert size of 150 bp and subjected to Illumina
DNA sequencing library preparation using Bravo auto-
mated liquid handling platform. Sequencing was per-
formed on an Illumina HiSeq2000 machine using the
75 bp paired-end protocol with the target of 1 Gb
sequence per sample. Data quality was checked for 95%
target coverage at 100× and mutation analysis was
performed using an in-house algorithm. Sequencing
reads are aligned to the National Center for Bio-
technology Information (NCBI) build 37 human genome
using the BWA algorithm with Smith–Waterman cor-
rection with PCR duplicates removed56. Base substitu-
tions, small insertions or deletions and breakpoints were
identified by comparison against an unmatched control
using established bioinformatic algorithms: CaVEMan
for mutations57; Pindel to detect insertions and dele-
tions58; and CNVKit for copy number detection (https://
github.com/etal/cnvkit). The control used is an
unmatched blood sample sequenced to an equivalent
depth. To account for the absence of matched control, a
bespoke variant selection pipeline was developed. To
enrich for high-confidence somatic variants, there was
further filtering by removing: known constitutional
polymorphisms using human variation databases:
Ensembl GRCh37.5, 1000 genomes release 2.2.2 and
ESP6500; and alterations where the same sequence
change was present at least twice in exome or whole-
genome sequencing data derived from 317 constitu-
tional (normal) DNA samples.
Primers and probes
The Primer Express (v3.0) software (Applied Biosys-
tems™) was used to design custom primers and probes for
various assays. Primers were designed to be 18–26 bp in
length, 40–60% GC content and within the melting
temperature (Tm) range of 58–62 °C. The length of the
amplicon was limited to <100 base pairs. Tentative primer
pairs were then analyzed with the University of California,
Santa Cruz (UCSC) in silico PCR platform (https://
genome.ucsc.edu/cgi-bin/hgPcr). Primer pairs were vali-
dated using SYBR Green Real-Time PCR. To ensure that
probes annealed to their target alleles before primer-
target hybridization occurred, TaqMan™ Minor-Binding-
Groove (MGB) probes were designed to be approximately
10 °C higher in Tm compared to their primer counter-
parts. Probe were designed to discriminate WT and
mutant sequences, other parameters included 15–20 bp in
length, 40–60% GC content, and the last 5 nucleotides at
3’ to contain no more than 2 G/C nucleotides to avoid the
“GC clamping” effect. For mutation-specific probes, the
mutant bases were placed in the middle of the amplicon
for optimal mismatch discrimination59. Peptide nucleic
acids (PNAs; Eurogentec, Belgium) were designed as
13–15b oligomers with the Tm of ~70 °C (~10 °C higher
than Tm of primers) and sequences complimentary to WT
alleles.
DNA quantification of patient plasma samples
The quantification analysis was run on the StepOne-
PlusTM Real-Time PCR System Thermal Cycling Block
(ABI®). Plasma DNA samples were quantified using an
intronic sequence of the housekeeping human GAPDH
gene. Then, 10 ng of human genomic DNA (hgDNA)
control (Roche, Germany) was diluted 1:2 ratio in H2O for
7–8 dilutions in triplicate to construct a standard curve.
The assay was run in a 10 μL reaction volume containing
5 μL 2× TaqMan® Genotyping PCR Master Mix, 600 nM
primers, 100 nM of the TaqMan probe and 3 μL of DNA
sample. The PCR program was 50 °C for 2 min, 95 °C for
10min and 50 cycles of 95 °C for 15 s followed by 60 °C
for 1 min at ramp rate of 1.6 °C/s. Data analysis was done
on the StepOnePlusTM Software v2.3 (ABI®). Primers and
probe sequences are reported in Supplemental Table 5.
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DNA quantification of patient FFPE samples
Patient FFPE tissue DNA samples were quantified using
an assay designed to amplify a 69 bp targeting the Alu
retrotransposon elements60. Next, 10 ng of human geno-
mic DNA (Roche) was diluted 1:2 ratio in H2O for 7–8
dilutions to construct a standard curve. Each dilution was
run in triplicate. Reactions were run in 10 μL volumes
containing 5 μL 2× TaqMan® Genotyping PCR Master
Mix, 600 nM of each primer, 100 nM probe and 3 μL of
DNA sample. The assay was run using the programme:
50 °C for 2 min, 95 °C for 10min and 50 cycles of 95 °C for
15 s followed by 60 °C for 1 min.
BRAF and KRAS mutation analysis on FFPE samples using
real-time PCR
The three assays BRAF-c.1799, KRAS-c.34 and KRAS-
c.35 were run on StepOnePlusTM Real-Time PCR (ABI®).
The mutant probe for the KRAS-c.34 and KRAS-c.35
assays incorporate a degenerate D (A/T/G) nucleotide for
the detection of three possible missense point mutations
at each hotspot. To enhance detection of the mutant
DNA, WT gene signal was inhibited using peptide nucleic
acid (PNA)61: 150 nM of PNA per reaction well for the
BRAF-c.1799 assay and 60 nM of PNA for the KRAS-c.34
and KRAS-c.35 assays. The BRAF-c.1799 and KRAS-c.35
assays were run in 10 μL reaction volumes containing 5 μL
of 2× TaqMan® Genotyping PCR Master Mix, 600 nM
primers and 100 nM of WT and mutant probes. Each
reaction contained 3 μL of sample and each sample was
run in triplicate. The PCR program was: holding stage at
50 °C for 2 min followed by 95 °C at 10min, then 50 cycles
of 95 °C for 15 s and 60 °C for 1 min at ramp rate of
1.6 °C/s. Data analysis was done on the StepOnePlusTM
Software v2.3 (ABI®). Primer, probe and PNA sequences
are reported in Supplemental Table 5.
Mutation detection assays using the ddPCR system
All ddPCR assays were run on the QX200TM ddPCR
system (BioRad). Each sample was run in 20 μL volume
containing 10 μL ddPCR Supermix for Probes (BioRad).
Within 1 h of droplet generation, reaction plates were run
on the C1000 TouchTM Thermal Cycler with 96-Deep
Well Reaction Module at a ramp rate of 2 °C/s. The FFPE
DNA samples were checked for point mutations using
sequence-specific TaqMan probes. For all assays, except
KRAS-c.38, each sample was tested in 20 μL reaction
volumes containing respective 450 nM of each primer,
and WT and mutant probe at 250 nM. The KRAS-c.38
assay was run in a 20 μL reaction volume containing 10 μL
ddPCR Supermix for Probes, 1 μL each of KRAS-c.35 WT
and mutant mixes (dHsaCP2000013-14; BioRad®). The
three mutation assays, BRAF-c.1799, KRAS-c.34 and
KRAS-c.35, were run on the following program: enzyme
activation at 95 °C for 10min, 40 cycles of denaturation
and extension at 94 °C for 30 s and 59 °C for 1 min,
respectively, enzyme deactivation at 98 °C for 10min with
holding at 4 °C. The KRAS-c.38 assay was also run on the
same PCR program except at 55 °C for 1 min during the
extension stage. The APC-c.4012, APC-c.4189, TP53-c.817
and PI3K-c.3140 assays were run using the same PCR
program except at 57 °C for 1 min during the extension
stage. As for the APC-c.4285 assay, the extension tem-
perature was increased to 60 °C for 1 min. Primers and
probe sequences are reported in Supplemental Table 1.
Droplets were read using the QX200TM Droplet Reader
and data analyzed with QuantaSoftTM software (version
1.6.6.0320). Threshold calling was set at the limit of
detection (LoD), which is defined by the minimum target
concentration that can be discriminated from the non-
target (WT) background. Assuming a false-positive rate of
0 droplet and a LoD of 0.01% for single-well assays, at
least 3 mutant copies need to be detected above the
fluorescence threshold in each well for positive target
(mutant) calling at 95% statistical confidence interval.
cfDNA-like positive control containing BRAF-T1799A
and KRAS-G35 mutations was purchased from SeraCare
and 10 ng was run on the ddPCR platform.
DNA quantification of murine samples
To quantify murine DNA samples, we implemented a
ddPCR assay (BioRad QX200) for amplification of mouse
Gapdh pseudogenes42. To construct a standard curve,
10 ng of mouse genomic DNA control (Promega) was
diluted in 1:2 ratios in H2O for 7–8 dilutions. Each dilu-
tion was run in either duplicate or triplicate. Reactions
were run in 10 μL volume containing 5 μL 2× TaqMan®
Genotyping PCR Master Mix, 600 nM of each primer,
100 nM probe and 3 μL of sample. The qPCR was run
using the following program: 50 °C for 2 min, 95 °C for
10min and 50 cycles of 95 °C for 15 s followed by 60 °C
for 1 min. Primer and probe sequences are reported in
Supplemental Table 6.
Analysis of recombined alleles in Lgr5CreER-Apcfl/fl mice
Reactions were run on BioRad QX200 digital PCR
platform in a 10 μL volume containing 5 μL 2× TaqMan®
Genotyping PCR Master Mix, 600 nM of each primer,
100 nM of probe and 3 μL of sample. The assay was run
using the following program: 50 °C for 2 min, 95 °C for
10min and 50 cycles of 95 °C for 15 s followed by 60 °C
for 1 min. Primers and probe sequences are reported in
Supplemental Table 6.
Statistical analysis
Total plasma cfDNA concentrations between the con-
trol and experimental groups were analyzed using Stu-
dent's t-test or non-parametric Mann-Whitney test.
Efficiencies of real-time PCR and ddPCR assays were
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calculated using linear regression analysis. For all muta-
tion detection assays performed on ddPCR, Poisson dis-
tribution analysis was used to predict the probability of
independent and random distribution of targets into
droplets at 95% confidence level. Data were analyzed
using GraphPad Prism 7 or Excel software packages,
unless otherwise stated.
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